Cytek Biosciences shares surge 13.92% premarket after TIME recognition and reaffirmed 2025 revenue guidance boost investor confidence.

Cytek Biosciences surged 13.92% in premarket trading following its inclusion in TIME’s 2026 America’s Growth Leaders list, which highlighted the company’s innovation in spectral flow cytometry and its impact on biomedical research. This recognition, coupled with the firm’s reaffirmation of its 2025 full-year revenue guidance despite ongoing net losses, signaled confidence in its recurring revenue streams and technological leadership. The news bolstered investor sentiment, though challenges such as margin pressures and sluggish capital equipment demand remain key risks. The premarket rally reflects optimism around the company’s long-term growth narrative and its ability to leverage industry visibility into sustained revenue gains.